Immtech: Pafuramidine Trial Gets Fast-Track Status In China (China)
This article was originally published in PharmAsia News
Executive Summary
China's State Food and Drug Administration has granted Immtech Pharmaceuticals' application for fast-track status for conducting a Phase III clinical trial involving pafuramidine. Pafuramidine is the company's oral drug candidate for the treatment of Pneumocystis pneumonia, a fungal infection in the lungs that can cause potentially life-threatening pneumonia in patients with HIV and other immune-related diseases. (Click here for more - May Require Paid Subscription
You may also be interested in...
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.